| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/10/2001 | EP1066271A1 Thiocarboxamide derivatives and their use as inhibitors of alpha-4 integrins |
| 01/10/2001 | EP1066268A1 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists |
| 01/10/2001 | EP1066266A1 Cyclin dependent kinase inhibitors |
| 01/10/2001 | EP1066262A1 Imidazolone anorectic agents: i. acyclic derivatives |
| 01/10/2001 | EP1066261A1 Pyridine derivative and pharmaceutical containing the same |
| 01/10/2001 | EP1066257A2 Heterocylic classes of compounds for the modulating tyrosine protein kinase |
| 01/10/2001 | EP1066247A1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| 01/10/2001 | EP1066061A1 Use of scatter factor to enhance angiogenesis |
| 01/10/2001 | EP1066059A1 Formulations for protection of peg-interferon alpha conjugates |
| 01/10/2001 | EP1066056A1 An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition |
| 01/10/2001 | EP1066051A1 Sciellin and uses thereof |
| 01/10/2001 | EP1066050A2 Application of hsp70 proteins |
| 01/10/2001 | EP1066048A1 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof |
| 01/10/2001 | EP1066043A2 Materials and methods relating to the treatment of conditions involving mast cells, basophils and eosinophils |
| 01/10/2001 | EP1066042A2 Steroidal saponins for treating alzheimer's disease |
| 01/10/2001 | EP1066041A1 THE USE OF ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY |
| 01/10/2001 | EP1066038A2 Use of cabergoline in the treatment of restless legs syndrome |
| 01/10/2001 | EP1066036A1 Agents with serotonin-related activity for the treatment for sleep apnea |
| 01/10/2001 | EP1066033A1 Smilagenin and anzurogenin-d for the treatment of alzheimer's disease |
| 01/10/2001 | EP1065931A1 Compositions containing a combination of a creatine compound and a second agent |
| 01/10/2001 | EP1056722A4 Bisulfate salt of hiv protease inhibitor |
| 01/10/2001 | EP0742791B1 Macrocyclic difluorostatone derivatives useful as antiviral agents |
| 01/10/2001 | CN1279690A Soluble single-chain T-cell receptor proteins |
| 01/10/2001 | CN1279689A Vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 01/10/2001 | CN1279686A Inhibitors of nucleoside metabolism |
| 01/10/2001 | CN1279682A bicyclic kinase inhibitors |
| 01/10/2001 | CN1279681A Piperidylaminomethyltrifluoromethyl cyclic ether compound as p substance antagonist |
| 01/10/2001 | CN1279680A Imidazole derivatives with inhabiting activity to transterasa and preparing method thereof |
| 01/10/2001 | CN1279676A Pseudopolymorphic forms of z-[2-[4-(bis(4-fluorophenyl)methyl]-1-piperazinyl]ethozy] acetic and dihydrochloride |
| 01/10/2001 | CN1279673A ((Cyclo) alkyl substituted-.gamma.-aminobutyric acid derivatives (=GABA analogurs), their preparation and their use in the treatment of neurolog disorders |
| 01/10/2001 | CN1279670A Substituted oximes as neurokinin antagonists |
| 01/10/2001 | CN1279669A Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| 01/10/2001 | CN1279667A 4(3)-substituted-4(3)-aminonethyl-(thioxo)pyran(thiapyran)or-piperidine derivatives(=gabapendin analogues), their preparation and their use in treatment of neurological disorders |
| 01/10/2001 | CN1279617A Combination of an aldose reductase inhibitor and a glycogen phosphorglase inhibitor |
| 01/10/2001 | CN1279616A Synergistic composition and methods for treating neoplanstic or cancerous growths and for restoring or boosting hematopoiesis |
| 01/10/2001 | CN1279615A Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculation disorders |
| 01/10/2001 | CN1279614A Antistress agents and functional foods |
| 01/10/2001 | CN1279612A Modulation of immune responses |
| 01/10/2001 | CN1279606A Use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| 01/10/2001 | CN1279605A Inihibition of lipoprotein oxidation |
| 01/10/2001 | CN1279236A Salt as thrombin inhibitor |
| 01/10/2001 | CN1279090A Powdered medicine for conditioning viscera and whole body |
| 01/10/2001 | CN1060472C Hydroxamic acid derivatives with tricylic substitution, their preparing methods, medicines containing them and uses thereof |
| 01/10/2001 | CN1060465C Antianaphylaxis, anti-asthma and anti-inflammatory new medicine |
| 01/10/2001 | CN1060396C Pilose antler blood oral liquor |
| 01/10/2001 | CN1060367C Treatment health-care whip and medicated core thereof |
| 01/10/2001 | CN1060350C Chinese medicine for treatment of woman postpartum disease |
| 01/10/2001 | CN1060345C Nourishing liquid for building up strength |
| 01/09/2001 | US6172261 Biosynthesis using chain extension |
| 01/09/2001 | US6172256 Chiral-β-amino acid compounds and derivatives thereof |
| 01/09/2001 | US6172250 Hydrolysis of an organosilicon compounds |
| 01/09/2001 | US6172239 Psychological, nervous system disorders |
| 01/09/2001 | US6172237 Process for preparing eprosartan |
| 01/09/2001 | US6172229 1-phenyl-4-benzylpiperazines; dopamine receptor subtype specific ligands |
| 01/09/2001 | US6172209 Aminooxy-modified oligonucleotides and methods for making same |
| 01/09/2001 | US6172194 ARF-p19, a novel regulator of the mammalian cell cycle |
| 01/09/2001 | US6172187 Mammalian polypeptide associated with immune response; for the modulation of apoptosis |
| 01/09/2001 | US6172118 Administering 3-phenylcyclobutan-1-one derivatives to treat asthma and respiratory system disorders; phosphodiesterase inhibitors |
| 01/09/2001 | US6172108 Hydrazide compounds |
| 01/09/2001 | US6172100 Administering aminated 1-benzyl-2-phenylindole derivatives; benzylation |
| 01/09/2001 | US6172097 Treating psychological, eating, sexual, and nervous system disorders; anxiolytic, adrenergic blocking, and antidepressant agents; serotonin reuptake inhibitors |
| 01/09/2001 | US6172091 Metabolic calcium imbalance and osteoporosis |
| 01/09/2001 | US6172090 Side effect reduction by administering an insulin sensitivity enhancer such as pioglitazone hydrochloride with a biguanide such as metformin |
| 01/09/2001 | US6172089 Pharmaceutical composition |
| 01/09/2001 | US6172088 Administering gonadotropin releasing hormone inhibitor |
| 01/09/2001 | US6172080 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/09/2001 | US6172077 Tachykinin inhibitors; analgesics, antiinflammatory agents, antiemetics; neuralgia, headaches |
| 01/09/2001 | US6172074 Imidazopyridines and oxazolopyridines |
| 01/09/2001 | US6172072 Heterocyclically substituted benzamides and their use in fighting diseases |
| 01/09/2001 | US6172070 In polyoxyethylene glycol carrier |
| 01/09/2001 | US6172068 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 01/09/2001 | US6172062 Dihydrobenzodioxine carboxamide and ketone derivatives |
| 01/09/2001 | US6172060 Therapy for sexual disorders |
| 01/09/2001 | US6172055 Therapy, prevention a neurodegenerative diseases |
| 01/09/2001 | US6172042 Synthetic peptides that inhibit IL-6 activity |
| 01/09/2001 | US6171860 Oligonucleotides which target untranslated regions and start codons to prevent transcription of a gene; for treatment of bone disorders, inflammation and cancer; antiinflammatory agents; anticarcinogenic agents; antitumor agents |
| 01/09/2001 | US6171795 Nucleic acid ligands to CD40ligand |
| 01/09/2001 | US6171620 Method of enhancing the efficacy of anti-tumor agents |
| 01/09/2001 | US6171618 Combination dosage form comprising cetirizine and pseudoephedrine |
| 01/09/2001 | US6171603 Treating skin, hair, cardiovascular, autoimmune and vision disorders; administering as anticarcinogenic, antidepressant,antiinflammatory, and antiacne agents |
| 01/09/2001 | US6171598 GTP cyclohydrolase II (RIBA) |
| 01/09/2001 | US6171588 Anti-αvβ3 integrin antibody antagonists |
| 01/08/2001 | CA2314292A1 Topical cosmetic compositions comprising benzaldoximes |
| 01/04/2001 | WO2001001131A1 Screening methods for compounds that affect melanogenesis |
| 01/04/2001 | WO2001000880A2 Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype |
| 01/04/2001 | WO2001000859A1 Method of inducing angiogenesis by micro-organs |
| 01/04/2001 | WO2001000830A1 Sgip peptides |
| 01/04/2001 | WO2001000824A2 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 01/04/2001 | WO2001000822A2 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 01/04/2001 | WO2001000818A1 Gene encoding promoter domain of tumor suppressor gene p51 and use thereof |
| 01/04/2001 | WO2001000812A2 22012, a novel human carboxypeptidase |
| 01/04/2001 | WO2001000811A2 17867, a novel human aminopeptidase |
| 01/04/2001 | WO2001000808A1 Antisense modulation of ship-2 expression |
| 01/04/2001 | WO2001000670A1 Bh3 modified peptides |
| 01/04/2001 | WO2001000665A2 Inhibitors of memapsin 2 and use thereof |
| 01/04/2001 | WO2001000663A2 Catalytically active recombinant memapsin and methods of use thereof |
| 01/04/2001 | WO2001000660A1 INHIBITORS OF THE INTEGRIN αvβ¿6? |
| 01/04/2001 | WO2001000658A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/04/2001 | WO2001000655A2 Therapeutic peptides derived from subsequences of bpi |
| 01/04/2001 | WO2001000653A1 Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |